KR101176435B1 - Composition for the prevention and treatment metabolic disorders comprising extracts of Nelumbo nucifera leaf and Taurine - Google Patents
Composition for the prevention and treatment metabolic disorders comprising extracts of Nelumbo nucifera leaf and Taurine Download PDFInfo
- Publication number
- KR101176435B1 KR101176435B1 KR1020100015502A KR20100015502A KR101176435B1 KR 101176435 B1 KR101176435 B1 KR 101176435B1 KR 1020100015502 A KR1020100015502 A KR 1020100015502A KR 20100015502 A KR20100015502 A KR 20100015502A KR 101176435 B1 KR101176435 B1 KR 101176435B1
- Authority
- KR
- South Korea
- Prior art keywords
- taurine
- lotus leaf
- leaf extract
- fat
- composition
- Prior art date
Links
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 title claims abstract description 176
- 240000002853 Nelumbo nucifera Species 0.000 title claims abstract description 107
- 235000006508 Nelumbo nucifera Nutrition 0.000 title claims abstract description 106
- 229960003080 taurine Drugs 0.000 title claims abstract description 88
- 230000002265 prevention Effects 0.000 title claims description 6
- 239000000284 extract Substances 0.000 title abstract description 105
- 239000000203 mixture Substances 0.000 title abstract description 47
- 208000030159 metabolic disease Diseases 0.000 title abstract description 15
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 19
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 19
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 19
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 100
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 235000013402 health food Nutrition 0.000 claims description 8
- 239000000469 ethanolic extract Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000006872 improvement Effects 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 19
- 208000016097 disease of metabolism Diseases 0.000 abstract description 4
- 235000009200 high fat diet Nutrition 0.000 description 58
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 44
- 235000021590 normal diet Nutrition 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 235000019197 fats Nutrition 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 20
- 238000009825 accumulation Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 235000012000 cholesterol Nutrition 0.000 description 14
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 12
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 10
- 108010082126 Alanine transaminase Proteins 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000008214 LDL Cholesterol Methods 0.000 description 9
- 206010067125 Liver injury Diseases 0.000 description 9
- 231100000234 hepatic damage Toxicity 0.000 description 9
- 230000008818 liver damage Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 230000004580 weight loss Effects 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 208000008589 Obesity Diseases 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 235000020824 obesity Nutrition 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 210000001789 adipocyte Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 210000002216 heart Anatomy 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 210000005228 liver tissue Anatomy 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 238000001543 one-way ANOVA Methods 0.000 description 5
- -1 patch Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 230000009395 genetic defect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 2
- 239000001230 potassium iodate Substances 0.000 description 2
- 235000006666 potassium iodate Nutrition 0.000 description 2
- 229940093930 potassium iodate Drugs 0.000 description 2
- 206010036596 premature ejaculation Diseases 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- HYPYXGZDOYTYDR-HAJWAVTHSA-N 2-methyl-3-[(2e,6e,10e,14e)-3,7,11,15,19-pentamethylicosa-2,6,10,14,18-pentaenyl]naphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 HYPYXGZDOYTYDR-HAJWAVTHSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241001107116 Castanospermum australe Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 235000005807 Nelumbo Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000007180 Sunstroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000001576 beta-amino acids Chemical group 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000021279 black bean Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940078495 calcium phosphate dibasic Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940116318 copper carbonate Drugs 0.000 description 1
- 229910000009 copper(II) carbonate Inorganic materials 0.000 description 1
- GEZOTWYUIKXWOA-UHFFFAOYSA-L copper;carbonate Chemical compound [Cu+2].[O-]C([O-])=O GEZOTWYUIKXWOA-UHFFFAOYSA-L 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000011646 cupric carbonate Substances 0.000 description 1
- 235000019854 cupric carbonate Nutrition 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- XMWCXZJXESXBBY-UHFFFAOYSA-L manganese(ii) carbonate Chemical compound [Mn+2].[O-]C([O-])=O XMWCXZJXESXBBY-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 229940082820 nelumbo nucifera leaf extract Drugs 0.000 description 1
- 230000004007 neuromodulation Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 125000000946 retinyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C([H])=C(C([H])([H])[H])/C([H])=C([H])/C1=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])C1(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940045613 taurine 1000 mg Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000011667 zinc carbonate Substances 0.000 description 1
- 235000004416 zinc carbonate Nutrition 0.000 description 1
- 229910000010 zinc carbonate Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Abstract
본 발명은 고지혈증 또는 지방간 예방 및 치료용 조성물에 관한 것으로서, 보다 상세하게는 연잎(Nelumbo nucifera leaf) 추출물 및 타우린을 유효성분으로 함유하는 대사성 질환인 고지혈증 또는 지방간 예방 및 치료용 조성물에 관한 것이다. The present invention relates to a composition for preventing and treating hyperlipidemia or fatty liver, and more particularly, to a composition for preventing and treating hyperlipidemia or fatty liver, which is a metabolic disease containing an extract of Nelumbo nucifera leaf and taurine as an active ingredient.
Description
본 발명은 연잎(Nelumbo nucifera leaf) 추출물 및 타우린을 함유하는 대사성 질환인 고지혈증 또는 지방간 예방 및 치료제에 관한 것이다.
The present invention relates to a drug for preventing and treating hyperlipidemia or fatty liver, which is a metabolic disease containing Nelumbo nucifera leaf extract and taurine.
대사장애는 일반적으로 심혈관 질병을 결정짓는 위험 요소로, 비만, 당뇨병, 인슐린 저항증(insulin resistance), 지질 대사 이상, 고중성지방혈증 (hypertriglyceridemia), 유리지방산의 증가, 고밀도 콜레스테롤의 감소 및 고혈압 등의 병들이 대사성 질환에 포함된다. 대사장애는 유전적인 결함으로 인해서 신체의 대사과정에 문제가 생김으로 발생한다. 대부분 대사장애의 유전적 결함은 부모로부터 유전되며, 대사장애의 원인이 되는 유전자의 종류는 다양하다고 밝혀졌다. 대사과정은 신체에서 섭취한 음식물을 사용할 수 있는 에너지로 전환하는 일련의 과정을 일컫는다. 신체는 효소를 이용하여 음식물을 잘게 분해한 후 소화시킬 수 있는 간단한 형태로 만든다. 또한 세포 내의 또 효소는 음식물로부터 섭취할 수 없는 형태의 물질을 에너지원으로 사용하기 위하여 생성하는 역할을 한다. 즉, 대사장애의 유전적인 결함은 대사에 필요한 효소가 정상적으로 활동할 수 없거나, 신체가 생성하는 효소의 양이 극도로 감소하거나, 없어지는 경우에 발생한다. 또한 유전적 결함으로 인해 섭취된 물질이 분해되지 않고, 신체 내에서 독성을 갖게 되는 경우도 발생하며, 신체에서 필요한 물질을 대사과정을 통해서 공급할 수 없는 결과가 초래되기도 한다. Metabolic disorders are generally a risk factor that determines cardiovascular disease, including obesity, diabetes, insulin resistance, lipid metabolism disorders, hypertriglyceridemia, increased free fatty acids, decreased high-density cholesterol, and high blood pressure. Diseases are involved in metabolic diseases. Metabolic disorders are caused by problems with the body's metabolic processes due to genetic defects. Most genetic defects of metabolic disorders are inherited from parents, and the genes that cause metabolic disorders have been found to vary. Metabolic processes are a series of processes that convert the body's food into energy for use. The body uses enzymes to break down food into smaller forms that can be digested. In addition, enzymes in the cell also play a role in producing substances that cannot be consumed from food as energy sources. In other words, genetic defects of metabolic disorders occur when enzymes necessary for metabolism cannot function normally or the amount of enzymes produced by the body is extremely reduced or disappeared. In addition, genetic defects cause ingested substances not to be degraded and become toxic in the body, and the result is that the body cannot supply the necessary substances through metabolic processes.
현대 사회에서 비만은 다양한 원인에 의해 체내의 지방 축적량이 증가하여 발생되고 있으며, 체내의 과도한 지방 축적의 위험에 대해서는 그리스 시대부터 알려졌다고 하나, 이로 유도되는 병에 대해서는 지난 세기 비만이 영양부족을 제치고 주요한 문제로 자리매김하면서 그 중요성이 평가되기 시작하였다. 또한, 비만은 고혈압, 당뇨병, 심장질환, 동맥경화, 고지혈증과 같은 대사성 질환으로 발전 될 수 있기 때문에 그 치료와 예방이 중요하다. 또한 근래에는 비만, 당뇨병, 고지혈증 등의 증가로 비알코올성 지방 간염이 증가하고 있으며, 일부는 간경변증으로 진행되는 것으로 알려져 있다. 더욱이 지방간이 단순한 간 질환이 아니라 대사 질환의 초기 증상으로 여겨지면서 비만으로 인한 지방간의 조기 진단과 치료의 중요성이 커지고 있다.In modern society, obesity is caused by increased fat accumulation in the body due to various causes, and the risk of excessive fat accumulation in the body has been known since the Greek era. As it became a major problem, its importance began to be evaluated. In addition, since obesity can develop into metabolic diseases such as hypertension, diabetes, heart disease, arteriosclerosis, and hyperlipidemia, its treatment and prevention are important. In recent years, non-alcoholic fatty hepatitis is increasing due to an increase in obesity, diabetes, hyperlipidemia, and some are known to progress to cirrhosis. Moreover, as fatty liver is regarded as an early symptom of metabolic disease rather than just liver disease, the importance of early diagnosis and treatment of fatty liver due to obesity is increasing.
비만을 예방하고 치료하기 위해서 지방의 흡수를 억제하거나, 식욕을 저하하는 목적으로 다양한 식이요법, 운동요법, 정신요법 등을 선택하며, 이런 방법이 충분하지 않은 경우에는 중추성 식욕억제제, 지방의 흡수를 막는 흡수 억제제, 혹은 콜레스테롤 혹은 중성 지방의 강하제, 항산화제 등의 약물 치료를 병행하게 된다. 그러나 현재까지 비만 치료제로 사용되는 이러한 약물들은 불면증, 발진, 메스꺼움, 두통, 발진 등 많은 부작용이 있다.
To prevent and treat obesity, various diet, exercise, and psychotherapy are selected for the purpose of suppressing the absorption of fat or lowering appetite.If this is not sufficient, central appetite suppressant and absorption of fat The drug may be treated with anti-absorption inhibitors, cholesterol or triglyceride lowering agents, or antioxidants. However, these drugs used to treat obesity so far have many side effects such as insomnia, rash, nausea, headache and rash.
연(Nelumbo nucifera)은 민간요법으로 널리 활용되어 왔다. 연의 잎, 뿌리, 줄기, 꽃, 열매, 어린 눈과 어린 뿌리에 이르기까지 다양한 부위가 채취되어 약재로서 이용되어 왔다. 잎은 파쇄하여 설사를 치료하는데 사용하고, 감초와 함께 달여서 일사병을 치료하는데 사용하였다. 꽃잎은 달여서 조루증을 치료하고, 꽃 턱받침은 달여서 복부의 경련이나 하혈을 치료하는데 사용하였다. 또한, 연꽃 줄기는 위궤양이나 생리 혹은 산후 출혈이 심한 경우에 지혈을 위해서 사용되었다. 꽃의 수술은 빈뇨, 조루, 체내에서 적혈구가 붕괴하여 헤모글로빈(hemoglobin)이 혈구(血球) 밖으로 용출되는 용혈증상 혹은 여성의 하혈을 방지하는데에 사용되었다. 열매는 달여서 불안, 열, 심장 통증에, 씨앗에는 알칼로이드(alkaloids)와 플라보노이드(flavonoids) 가 함유되어, 혈압강하, 혈관 확장 및 진정제로 사용되었다. 연의 씨앗은 콜레스테롤 수치를 낮추며, 자궁의 평활근을 이완시키며 소화장애, 장염, 만성설사, 정액루(spermatorrhoea, 精液漏), 불면증, 심박수 이상 등에 사용되었다.
Nelumbo nucifera ) has been widely used as a folk remedy. Various parts of the leaves, roots, stems, flowers, fruits, young eyes and young roots of lotuses have been collected and used as medicinal herbs. The leaves were crushed and used to treat diarrhea and decoction with licorice to treat sunstroke. The petals were decocted to treat premature ejaculation and the flower bib was decocted to treat abdominal cramps and bleeding. Lotus stems were also used for hemostasis in severe ulcers, menstrual or postpartum bleeding. Flower surgery has been used to prevent hemolysis or female bleeding, in which hemoglobin dissolves out of the blood cells because of red blood cells collapse in the urine, premature ejaculation, and the body. The fruit is sweetened to anxiety, fever, and heart pain, and the seeds contain alkaloids and flavonoids, which are used for lowering blood pressure, vasodilation and sedation. Seeds of lotus lower cholesterol levels, relax the smooth muscles of the uterus, and have been used for digestive disorders, enteritis, chronic diarrhea, spermatorrhoea, insomnia, and heart rate abnormalities.
타우린(taurine, 2-aminoethane sulfonic acid)은 체내에서 단백질 합성에 이용되지 않고 산화되어 에너지를 낼 수 있는 황(sulfer, S) 기가 α-탄소에 치환되어 있으며, 아미노기가 분자구조의 β-탄소에 붙어있는 β-아미노산이며, α-탄소에 치환되어 있는 황으로 인해 pK값이 낮아 다른 아미노산에 비해 더 낮은 pH에서도 쉽게 이온화되는 성질이 있다. 포유류의 뇌, 심장, 간, 신장과 골격 근육, 혈구세포 등에 고농도로 존재하며, 세포외액에 비하여 세포내액에 매우 높은 농도로 존재한다. 주로 신경조절작용, 세포막의 안정화, 해독 작용, 항산화작용을 나타내고 고혈압 개선에도 관여하는 것으로 알려져 있으나, 그 정확한 기작은 밝혀지지 않고 있다.(Chang K.J., Korean J. Nutr . 32(3): 213-220. 1999; Kishida T. et al ., J. Nutr . 133(8): 2616-2621, 2003; Chen W. et al ., Life Sci . 74(15): 1889-1898, 2004).
Taurine (taurine, 2-aminoethane sulfonic acid) is not used for protein synthesis in the body. Sulfur (S) groups, which can be oxidized and give energy, are substituted for α-carbon. It is a β-amino acid attached and has a property of easily ionizing at a lower pH than other amino acids due to low pK value due to sulfur substituted in α-carbon. It is present at high concentrations in the brain, heart, liver, kidney and skeletal muscles, blood cells of mammals, and in very high concentrations in intracellular fluids compared to extracellular fluids. It is known to be mainly involved in neuromodulation, stabilization of cell membranes, detoxification, antioxidant activity and improvement of hypertension, but the exact mechanism is unknown . (Chang KJ, Korean J. Nutr . 32 (3): 213-220. 1999; Kishida T. et al . , J. Nutr . 133 (8): 2616-2621, 2003; Chen W. et al . , Life Sci . 74 (15): 1889-1898, 2004).
이에, 본 발명자들은 고지방식이군을 먹인 Sprague-Dawley 수컷 쥐에게 연잎 추출물 및 타우린을 경구 투여하여 연잎 추출물 및 타우린의 기능성을 규명한 결과, 체중의 감소, 지방 및 간 세포의 지방 축적 저하, 혈청 내 HDL 콜레스테롤 함량의 증가와 LDL 콜레스테롤의 감소 및 간 손상 수치를 나타내는 GPT, GOT의 수치가 감소하는 것을 확인함으로써, 본 발명을 완성하였다.
Therefore, the present inventors orally administered lotus leaf extract and taurine to Sprague-Dawley male rats fed the high-fat diet group to find the functionalities of the lotus leaf extract and taurine, resulting in weight loss, fat accumulation of fat and liver cells, and serum The present invention has been completed by confirming that the levels of GPT and GOT, which are indicative of an increase in HDL cholesterol and a decrease in LDL cholesterol and liver damage, are decreased.
본 발명은 연잎(Nelumbo nucifera leaf) 추출물 및 타우린을 유효성분으로 함유하는 고지혈증 또는 지방간의 예방 및 치료용 조성물 및 건강식품을 제공하는 것이다.
The present invention provides a composition for preventing and treating hyperlipidemia or fatty liver and health food containing the lotus leaf ( Nelumbo nucifera leaf) extract and taurine as an active ingredient.
상기 목적을 달성하기 위하여, 본 발명은 연잎(Nelumbo nucifera leaf) 추출물 및 타우린을 유효성분으로 함유하는 고지혈증 또는 지방간의 예방 및 치료용 조성물을 제공하는 것이다. In order to achieve the above object, the present invention is to provide a composition for preventing and treating hyperlipidemia or fatty liver containing lotus leaf ( Nelumbo nucifera leaf) extract and taurine as an active ingredient.
아울러, 본 발명은 연잎 추출물 및 타우린을 함유하는 고지혈증 또는 지방간의 예방 및 개선용 건강식품을 제공한다.
In addition, the present invention provides a health food for preventing and improving hyperlipidemia or fatty liver containing lotus leaf extract and taurine.
본 발명의 타우린과 연잎의 열수 추출물을 고지방식이와 함께 쥐에게 먹였을 때, 체중의 감소, 지방 및 간 세포의 지방 축적 저하, 혈청내 HDL 콜레스테롤 함량의 증가과 LDL 콜레스테롤의 감소 및 간손상 수치를 나타내는 GPT, GOT의 수치가 감소되는 것을 확인함으로써, 타우린과 연잎 추출물을 대사성 질환인 고지혈증 또는 지방간 예방 및 치료용 조성물 및 건강식품으로 사용될 수 있다.
When hot water extracts of taurine and lotus leaf of the present invention were fed to rats with a high fat diet, weight loss, fat and liver cell fat accumulation, serum HDL cholesterol and serum LDL cholesterol, and liver damage were measured. By confirming that the levels of GPT and GOT are reduced, taurine and lotus leaf extract can be used as a composition for preventing and treating hyperlipidemia or fatty liver, which is a metabolic disease, and as a health food.
도 1은 연잎 추출물과 타우린의 체중감소의 효과를 나타낸 그래프이다:
N: 정상식이군;
HF: 고지방식이군;
HFL: 고지방식이군에 연잎 추출물 경구 투여한 군;
HFLT: 고지방식이군에 연잎 추출물 및 타우린을 투여한 군; 및
*: p<0.05 의 유의수준에서 3군 간의 차이가 있음을 의미함.
도 2는 연잎 추출물과 타우린의 지방 축적 저해 효과를 지방 조직에서 확인한 그림이다:
N: 정상식이군;
HF: 고지방식이군;
HFL: 고지방식이군에 연잎 추출물 경구 투여한 군; 및
HFLT: 고지방식이군에 연잎 추출물 및 타우린을 투여한 군.
도 3은 연잎 추출물과 타우린의 지방 축적 저해 효과를 간 조직에서 확인한 그림이다:
N: 정상식이군;
HF: 고지방식이군;
HFL: 고지방식이군에 연잎 추출물 경구 투여한 군; 및
HFLT: 고지방식이군에 연잎 추출물 및 타우린을 투여한 군.
도 4는 연잎 추출물과 타우린의 혈중 콜레스테롤 축적 저해 효과를 확인한 그래프이다:
N: 정상식이군;
HF: 고지방식이군;
HFL: 고지방식이군에 연잎 추출물 경구 투여한 군;
HFLT: 고지방식이군에 연잎 추출물 및 타우린을 투여한 군; 및
a, b : 일원분산분석 후 Duncan's multiple range test로 사후 검증시 유의수준 p<0.05 에서 차이가 있음을 의미함.
도 5은 연잎 추출물과 타우린의 HDL-콜레스테롤 함량을 총 콜레스테롤을 기준으로 나타낸 그래프이다:
N: 정상식이군;
HF: 고지방식이군;
HFL: 고지방식이군에 연잎 추출물 경구 투여한 군;
HFLT: 고지방식이군에 연잎 추출물 및 타우린을 투여한 군; 및
a, b : 일원분산분석 후 Duncan's multiple range test로 사후 검증시 유의수준 p<0.05 에서 차이가 있음을 의미함.
도 6은 연잎 추출물과 타우린의 혈중 LDL-콜레스테롤 감소 효과를 나타낸 그래프이다:
N: 정상식이군;
HF: 고지방식이군;
HFL: 고지방식이군에 연잎 추출물 경구 투여한 군;
HFLT: 고지방식이군에 연잎 추출물 및 타우린을 투여한 군; 및
a, b : 일원분산분석 후 Duncan's multiple range test로 사후 검증시 유의수준 p<0.05 에서 차이가 있음을 의미함.
도 7은 연잎 추출물과 타우린의 혈중 GPT와 GOT 활성 저해 효과를 확인한 그래프이다:
N: 정상식이군;
HF: 고지방식이군;
HFL: 고지방식이군에 연잎 추출물 경구 투여한 군;
HFLT: 고지방식이군에 연잎 추출물 및 타우린을 투여한 군;
a, b, c : 일원분산분석 후 Duncan's multiple range test로 사후 검증시 유의수준 p<0.05 에서 차이가 있음을 의미함; 및
ab: 일원분산분석 후 Duncan's multiple range test로 사후 검증시, a나 b라고 표시된 군과 유의적으로 차이가 없음을 의미함.1 is a graph showing the effect of weight loss of lotus leaf extract and taurine:
N: normal diet group;
HF: high fat diet;
HFL: Oral administration of lotus leaf extract to the high-fat diet group;
HFLT: lotus leaf extract and taurine in the high fat diet group; And
*: It means that there is a difference between 3 groups at the significance level of p <0.05.
Figure 2 is a figure confirming the fat accumulation inhibitory effect of the lotus leaf extract and taurine in adipose tissue:
N: normal diet group;
HF: high fat diet;
HFL: Oral administration of lotus leaf extract to the high-fat diet group; And
HFLT: The high-fat diet group was administered lotus leaf extract and taurine.
Figure 3 is a picture confirming the fat accumulation inhibitory effect of liver extract and taurine in liver tissue:
N: normal diet group;
HF: high fat diet;
HFL: Oral administration of lotus leaf extract to the high-fat diet group; And
HFLT: The high-fat diet group was administered lotus leaf extract and taurine.
Figure 4 is a graph confirming the effect of inhibiting the blood cholesterol accumulation of lotus leaf extract and taurine:
N: normal diet group;
HF: high fat diet;
HFL: Oral administration of lotus leaf extract to the high-fat diet group;
HFLT: lotus leaf extract and taurine in the high fat diet group; And
a, b: Duncan's multiple range test after one-way ANOVA means that there is a difference in significance level p <0.05 during post-test.
5 is a graph showing the HDL-cholesterol content of lotus leaf extract and taurine based on total cholesterol:
N: normal diet group;
HF: high fat diet;
HFL: Oral administration of lotus leaf extract to the high-fat diet group;
HFLT: lotus leaf extract and taurine in the high fat diet group; And
a, b: Duncan's multiple range test after one-way ANOVA means that there is a difference in significance level p <0.05 during post-test.
Figure 6 is a graph showing the LDL-cholesterol reducing effect of lotus leaf extract and taurine in blood:
N: normal diet group;
HF: high fat diet;
HFL: Oral administration of lotus leaf extract to the high-fat diet group;
HFLT: lotus leaf extract and taurine in the high fat diet group; And
a, b: Duncan's multiple range test after one-way ANOVA means that there is a difference in significance level p <0.05 during post-test.
7 is a graph confirming the inhibitory effect of GPT and GOT activity in blood of lotus leaf extract and taurine:
N: normal diet group;
HF: high fat diet;
HFL: Oral administration of lotus leaf extract to the high-fat diet group;
HFLT: lotus leaf extract and taurine in the high fat diet group;
a, b, c: Duncan's multiple range test after one-way ANOVA means that there is a difference in significance level p <0.05 during post-test; And
ab: After one-way analysis of variance, Duncan's multiple range test showed no significant difference from the group marked a or b.
이하, 본 발명을 상세히 설명한다.
Hereinafter, the present invention will be described in detail.
본 발명은 연잎(Nelumbo nucifera leaf) 추출물 및 타우린을 유효성분으로 함유하는 고지혈증 또는 지방간 예방 및 치료용 조성물을 제공한다.The present invention lotus leaf ( Nelumbo) nucifera It provides a composition for preventing and treating hyperlipidemia or fatty liver containing leaf) extract and taurine as an active ingredient.
본 발명의 유효성분인 연잎 추출물은 하기의 단계들을 포함하는 방법에 의해 제조되는 것이 바람직하나, 이에 한정되지 않는다: Lotus leaf extract as an active ingredient of the present invention is preferably prepared by a method comprising the following steps, but is not limited thereto:
1) 연잎 가루를 물, 알코올 또는 이들의 혼합물을 용매로 하여 추출하는 단계;1) extracting the lotus leaf powder with water, alcohol or a mixture thereof as a solvent;
2) 단계 2)의 추출물을 여과하는 단계;2) filtering the extract of step 2);
3) 단계 3)의 여과물을 감압 농축하는 단계; 및3) concentrating the filtrate of step 3) under reduced pressure; And
4) 단계 4)의 농축물을 동결 건조하는 단계.
4) freeze drying the concentrate of step 4).
본 발명의 제조방법에 있어서, 단계 1)의 연잎은 재배한 것 또는 시판되는 것을 제한 없이 사용할 수 있다.In the production method of the present invention, the lotus leaf of step 1) can be used without limitation, those grown or commercially available.
본 발명의 제조방법에 있어서, 단계 2)의 알코올은 C1 내지 C4의 저급 알코올 이용하는 것이 바람직하며, 저급 알코올로는 에탄올을 이용하는 것이 바람직하다. 추출시 용매를 연잎의 1/10 내지 1/70배 첨가하여 추출하는 것이 바람직하며, 1/40배 첨가하여 추출하는 것이 더욱 바람직하다. 상기 용매를 가한 후 환류 냉각하여 추출하는 것이 바람직하다. 추출시 물중탕의 물의 온도는 80℃ ~ 120℃인 것이 바람직하며, 90℃인 것이 더욱 바람직하나 이에 한정하지 않는다. 또한 추출시간은 30분 ~ 4시간이 바람직하며, 2시간이 바람직하나 이에 한정하지 않는다. 아울러 추출 횟수는 1 내지 3회인 것이 바람직하며, 2회 반복 추출하는 것이 더욱 바람직하나 이에 한정되는 것은 아니다. 상기 방법에 의하여 연잎을 추출, 감압여과한 뒤, 수분을 제거시켜 동결 건조하여 연잎 추출물을 수득하였다. In the production method of the present invention, the alcohol of step 2) is preferably C 1 to C 4 lower alcohol, it is preferable to use ethanol as the lower alcohol. It is preferable to extract by adding 1/10 to 1/70 times of the solvent at the time of extraction, and it is more preferable to add by extracting 1/40 times. After adding the solvent, reflux cooling is preferably performed. The temperature of the water in the water bath during extraction is preferably 80 ℃ ~ 120 ℃, more preferably 90 ℃ but not limited thereto. In addition, the extraction time is preferably 30 minutes to 4 hours, preferably 2 hours is not limited thereto. In addition, the number of extraction is preferably 1 to 3 times, it is more preferable to extract twice, but is not limited thereto. Lotus leaf was extracted by the above method, filtered under reduced pressure, and then water was removed to freeze-dry to obtain a lotus leaf extract.
본 발명의 제조방법에 있어서, 단계 3)의 감압농축은 진공 감압 농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정하지 않는다. In the production method of the present invention, the reduced pressure concentration of step 3) is preferably a vacuum reduced pressure concentrator or a vacuum rotary evaporator, but is not limited thereto.
본 발명의 제조방법에 있어서, 단계 4)의 건조는 감압건조, 진공건조, 비등건조, 분무건조 또는 동결건조하는 것이 바람직하나 이에 한정하지 않는다. In the manufacturing method of the present invention, the drying of step 4) is preferably reduced pressure drying, vacuum drying, boiling drying, spray drying or freeze drying, but not always limited thereto.
본 발명의 제조방법에 있어서, 단계 5)의 동결건조는 당업자에게는 상용화된 동결건조기를 구입하여, 그 사용절차에 따라 통상의 식품제조에서 널리 알려진바 대로 수행하는 것에 의해 용이하게 실시할 수 있을 정도로 공지된 것으로 이해될 수 있다.In the production method of the present invention, the lyophilization of step 5) is easily carried out by those skilled in the art by purchasing a commercially available freeze dryer, and performing it as is widely known in conventional food production according to the procedure for use thereof. It can be understood as known.
본 발명은 상기 제조방법에 의해 제조된 연잎 추출물 및 타우린을 유효성분으로 함유하는 고지혈증 또는 지방간 예방 및 치료용 조성물을 제공한다.
The present invention provides a composition for preventing and treating hyperlipidemia or fatty liver, which comprises lotus leaf extract and taurine prepared by the preparation method as an active ingredient.
본 발명의 실시예에서는 연잎 추출물 및 타우린의 고지혈증 또는 지방간 예방 및 치료용 조성물로서의 효능을 확인하기 위하여, 연잎을 물, 알코올 또는 이들의 혼합물을 용매로 하여 추출물을 획득하였다(실시예 1 참조).In the embodiment of the present invention, in order to confirm the efficacy of the lotus leaf extract and taurine as a composition for preventing and treating hyperlipidemia or fatty liver, the extract was obtained using lotus leaf as water, alcohol or a mixture thereof as a solvent (see Example 1).
본 발명의 한가지 실시예에서는 <실시예 1>의 연잎 추출물을 고지방식이를 공급한 쥐에게 경구투여하고, 타우린은 음용수에 3% 혼합하여 제공하였을 때, 체중이 연잎 추출물과 타우린을 단독으로 공급하였을 때에 비하여, 연잎 추출물과 타우린을 함께 투여하였을 때 감소하는 것을 확인할 수 있었다(도 1 참조). In one embodiment of the present invention, when the lotus leaf extract of <Example 1> was orally administered to rats fed a high fat diet, and taurine was provided by mixing 3% in drinking water, the weight of lotus leaf extract and taurine alone were supplied. Compared with when, it was confirmed that when the lotus leaf extract and taurine are administered together (see Fig. 1).
또한, 본 발명의 한가지 실시예에서는 지방 세포와 간 세포의 지방축적 형태를 관찰하였을 때, 정상식이에 비하여 고지방식이를 공급받은 쥐의 경우 세포의 모양이 커진 것을 확인할 수 있었고, 이를 통해 지방의 축적을 확인할 수 있었으며, 연잎 추출물과 타우린을 공급하였을 때에, 세포의 크기와 모양이 정상식이와 비슷하게 됨을 확인할 수 있었다(도 2 및 도 3 참조). In addition, in one embodiment of the present invention, when observing the fat accumulation form of the fat cells and liver cells, the rats fed a high-fat diet compared to the normal diet was confirmed that the shape of the cells increased, and through this Accumulation was confirmed, and when lotus leaf extract and taurine were supplied, the size and shape of the cells were confirmed to be similar to the normal diet (see FIGS. 2 and 3).
또한, 본 발명의 한가지 실시예에서는 연잎 추출물 및 타우린의 고지혈증 예방의 효과를 알아보기 위하여, 6주간의 연잎 추출물 및 타우린의 투여가 끝난 후, 심장으로부터 채혈한 혈액에서 콜레스테롤 수치를 측정한 결과, 총 콜레스테롤 수치가 정상식이에 비하여 고지방식이를 공급받은 군에서 증가하는 것을 확인할 수 있었으며, 연잎 추출물과 연잎 추출물 및 타우린을 공급받은 군에서 유의하게 감소되는 것을 확인할 수 있었다(도 4 참조). In addition, in one embodiment of the present invention, in order to determine the effect of preventing the hyperlipidemia of the lotus leaf extract and taurine, after the administration of the lotus leaf extract and taurine for 6 weeks, after measuring the cholesterol level in blood collected from the heart, total It was confirmed that the cholesterol level was increased in the group fed the high fat diet compared to the normal diet, and it was confirmed that the lotus leaf extract, lotus leaf extract and taurine significantly decreased in the group (see FIG. 4).
또한, 본 발명의 한가지 실시예에서는 연잎 추출물 및 타우린을 공급받은 경우에 연잎 추출물을 단독으로 공급받은 경우보다 더욱 유의하게 총콜레스테롤에 대한 HDL 콜레스테롤이 증가하는 것을 관찰할 수 있었다(도 5 참조). 특이할 만한 점은 연잎 추출물과 타우린을 공급받은 군의 총콜레스테롤에 대한 HDL 콜레스테롤 수치가 정상식이군과 거의 비슷하게 나타났다는 점이다. In addition, in one embodiment of the present invention, when the lotus leaf extract and taurine were fed, it was observed that the HDL cholesterol to total cholesterol was increased more significantly than the lotus leaf extract alone (see FIG. 5). It is unusual that the HDL cholesterol levels of total cholesterol in the lotus leaf extract and taurine supplemented groups were nearly the same as in the normal diet.
또한, 본 발명의 한가지 실시예에서는 LDL 콜레스테롤의 경우, 연잎 추출물 및 타우린을 공급받은 군에서 연잎 추출물을 단독으로 공급받은 군에 비해 감소하는 것을 확인할 수 있었다(도 6 참조). In addition, in one embodiment of the present invention, in the case of LDL cholesterol, the lotus leaf extract and the taurine-supplied group was confirmed to decrease compared to the group receiving the lotus leaf extract alone (see Fig. 6).
아울러, 본 발명의 한가지 실시예에서는 고지방식이군으로 인해서 손상된 간을 GPT, GOT의 수치로 확인한 결과, 정상식이군에 비해서 증가한 것을 확인할 수 있었으며, 이는 연잎 추출물을 제공하였을 때에 감소하며, 연잎 추출물 및 타우린을 공급하였을 때 더욱 유의하게 감소하는 것을 확인할 수 있었다(도 7 참조). In addition, in one embodiment of the present invention, as a result of confirming the liver damage due to the high-fat diet group by GPT, GOT, it was confirmed that the increase compared to the normal diet group, which decreases when providing the lotus leaf extract, lotus leaf extract and taurine It was confirmed that the significantly reduced when the supply (see Figure 7).
따라서, 본 발명의 연잎 추출물 및 타우린은 체중감소, 지방 및 간 조직의 지방 축적을 억제하며, 혈중 HDL 콜레스테롤을 증가시키는 반면, LDL 콜레스테롤의 수치를 감소시키는 효과를 보이며, 고지방식이로 인해 높아진 간 손상 수치인 GPT 및 GOT수치를 낮춰 간 손상의 회복에 효과를 가지므로 대사성 질환인 고지혈증 또는 지방간의 예방 및 치료용 조성물로 유용하게 사용될 수 있다.
Therefore, the lotus leaf extract and taurine of the present invention inhibit weight loss, fat accumulation of fat and liver tissue, increase the HDL cholesterol in the blood, while showing the effect of reducing the level of LDL cholesterol, elevated liver due to high fat diet Since the GPT and GOT levels, which are damage levels, are effective in restoring liver damage, they may be useful as compositions for the prevention and treatment of metabolic diseases such as hyperlipidemia or fatty liver.
발명의 조성물은 경구 또는 비경구 투여(예를 들어, 도포 또는 정맥 내, 피하, 복강 내 주사)할 수 있으나 경구 투여가 바람직하다. The compositions of the invention may be oral or parenteral (eg, applied or intravenous, subcutaneous, intraperitoneal), but oral administration is preferred.
비경구 투여를 위한 제제로는 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 멸균된 수용액, 액제, 비수성용제, 현탁제, 에멀젼, 시럽, 좌제, 에어로졸 등의 외용제 및 멸균 주사제제의 형태로 제형화하여 사용될 수 있으며, 바람직하게는 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라스마제의 피부 외용 약학적 조성물을 제조하여 사용할 수 있으나, 이에 한정하는 것은 아니다. 국소 투여의 조성물은 임상적 처방에 따라 무수형 또는 수성형일 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. Formulations for parenteral administration include powders, granules, tablets, capsules, sterile aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, syrups, suppositories, aerosols, etc. It may be used in the form of a formulation, and preferably, an external skin pharmaceutical composition of cream, gel, patch, spray, ointment, warning agent, lotion agent, linen agent, pasta agent or cataplasma agent may be prepared and used. It is not limited to this. Compositions of topical administration may be anhydrous or aqueous, depending on the clinical prescription. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
경구 투여를 위한 고형제제에는 산제, 과립제, 정제, 캡슐제, 연질캅셀제, 환 등이 포함된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제, 에어로졸 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. Solid form preparations for oral administration include powders, granules, tablets, capsules, soft capsules, pills and the like. Oral liquid preparations include suspensions, solvents, emulsions, syrups, and aerosols.In addition to commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. Can be.
상기 조성물은 투여를 위해서 연잎 추출물 및 타우린의 유효성분 이외에 추가로 약제학적으로 허용 가능한 담체를 1종 이상 포함하여 제조할 수 있다. 약제학적으로 허용 가능한 담체는 식염수, 멸균수, 링거액, 완충 식염수, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분 이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형 등으로 제제화할 수 있다. The composition may be prepared by additionally containing at least one pharmaceutically acceptable carrier in addition to the active ingredient of lotus leaf extract and taurine for administration. Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, as antioxidants, buffers And other conventional additives such as bacteriostatic agents can be added. In addition, diluents, dispersants, surfactants, binders and lubricants may be additionally added to formulate injectable formulations such as aqueous solutions, suspensions, emulsions and the like.
본 발명에 따른 약제학적으로 허용가능한 첨가제는 상기 조성물에 대해 0.1~90 중량부 포함되는 것이 바람직하다. The pharmaceutically acceptable additive according to the present invention is preferably included 0.1 to 90 parts by weight based on the composition.
본 발명의 조성물의 바람직한 투여량은 체내에서 활성성분의 흡수도, 환자의 연령, 성별 및 비만의 정도에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 경구 투여제의 경우 일반적으로 성인에게 1일에 체중 1㎏당 본 발명의 조성물을 1일 0.0001 내지 100 ㎎/㎏으로, 바람직하게는 0.001 내지 100 ㎎/㎏으로 투여하는 것이 좋다. 투여는 하루에 한번 투여할 수도 있고, 수회 나누어 투여할 수도 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다. Preferred dosages of the compositions of the present invention vary depending on the degree of absorption of the active ingredient in the body, the age, sex and obesity of the patient, but may be appropriately selected by those skilled in the art. For the desired effect, however, in the case of oral administration, it is generally advisable to administer the composition of the present invention to an adult at 0.0001 to 100 mg / kg / day, preferably 0.001 to 100 mg / kg, per kilogram of body weight per day. good. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.
본 발명의 고지혈증 또는 지방간 치료용 조성물은 연잎 추출물 및 타우린에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다.
The composition for treating hyperlipidemia or fatty liver of the present invention may contain one or more active ingredients exhibiting the same or similar functions in addition to the lotus leaf extract and taurine.
아울러, 본 발명은 연잎 추출물 및 타우린을 유효성분으로 함유하는 고지혈증 또는 지방간 예방 및 개선용 건강기능식품을 제공한다In addition, the present invention provides a dietary supplement for preventing and improving hyperlipidemia or fatty liver containing lotus leaf extract and taurine as an active ingredient.
본 발명의 연잎 추출물 및 타우린은 체중 감소, 지방 및 간 세포에서 지방축적 저하의 효과를 가지고, 혈중 HDL 콜레스테롤 수치는 향상시키는 반면, LDL 콜레스테롤의 수치를 감소시키는 효과를 가지며, 고지방식이로 인해 저하된 GPT, GOT 수치를 상승시키는 효과를 나타내므로, 대사성 질환인 고지혈증 또는 지방간을 예방 및 개선하는 효과를 갖는 건강식품의 유효성분으로 유용하게 이용될 수 있다.Lotus leaf extract and taurine of the present invention has the effect of weight loss, fat accumulation lowering in fat and liver cells, while improving the HDL cholesterol level in the blood, while having the effect of reducing the level of LDL cholesterol, and lowered by high fat diet Since GPT and GOT levels are increased, it can be usefully used as an active ingredient of health foods having the effect of preventing and improving metabolic diseases such as hyperlipidemia or fatty liver.
본 발명의 연잎 추출물 및 타우린은 식품학적으로 허용된 담체와 혼합하여 식품 조성물로서 제공될 수 있다. Lotus leaf extract and taurine of the present invention may be provided as a food composition by mixing with a food-acceptable carrier.
본 발명의 연잎 추출물 및 타우린을 식품 또는 음료 첨가물로 사용할 경우, 상기 연잎 추출물 및 타우린을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용되고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 상기 연잎 추출물 및 타우린의 비율은 그의 사용목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다.When the lotus leaf extract and taurine of the present invention are used as food or beverage additives, the lotus leaf extract and taurine may be added as they are or used together with other food or food ingredients, and may be appropriately used according to a conventional method. The ratio of the lotus leaf extract and taurine may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
건강 및 위생을 목적으로 하거나 또는 건강조절을 목적으로 하는 장기간의 섭취의 경우, 상기 연잎 추출물 및 타우린은 안전성 면에서 아무런 문제가 없기 때문에, 장기간 복용이 가능하다. In the case of long-term intake for health and hygiene or for health control, the lotus leaf extract and taurine have no problem in terms of safety, and therefore, long-term intake is possible.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿류, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있다.There is no particular limitation on the kind of the food. Examples of the food to which the substance can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, dairy products including other noodles, gum, ice cream, various soups, drinks, tea, and drinks. Alcoholic beverages and vitamin complexes.
음료수로 제형화할 경우에 연잎 추출물 및 타우린 이외에 첨가되는 액체 성분으로는 이제 한정되지는 않으나, 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드(예, 포도당, 과당 등), 디사카라이드(예, 말토오스, 수크로오스 등) 및 폴리사카라이드(예, 덱스트린, 시클로덱스트린 등과 같은 통상적인 당), 및 자일리톨, 소르비톨, 에리스리톨 등의 당 알코올이다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖ 당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다. 상술한 것 이외의 향미제로서 천연 향미제[타우마린, 스테비아 추출물(예, 레바우디오시드 A, 글리시르히진 등)] 및 합성 향미제(예, 사카린, 아스파르탐 등)를 사용할 수 있다.The liquid component added in addition to the lotus leaf extract and taurine when formulated into a beverage is not limited to now, but may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in conventional beverages. Examples of the natural carbohydrates described above include monosaccharides (e.g. glucose, fructose, etc.), disaccharides (e.g. maltose, sucrose, etc.) and polysaccharides (e.g. conventional sugars such as dextrins, cyclodextrins, etc.), and xylitol Sugar alcohols such as sorbitol and erythritol. The proportion of said natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention. As flavoring agents other than those described above, natural flavoring agents (taumarin, stevia extract (e.g., Rebaudioside A, glycyrzin, etc.)) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.) can be used. .
다른 양태로서, 본 발명의 식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 증진제 (치즈, 초콜릿 등), 펙트산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 또한 본 발명의 식품 조성물은 과일 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 단독으로 또는 조합으로 사용될 수 있으며, 이러한 첨가제의 비율은 조성물 전체 중량당 0.001 내지 50 중량부의 범위에서 선택되는 것이 일반적이다.
In another embodiment, the food composition of the present invention comprises various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, colorants and enhancers (such as cheese, chocolate), pectic acid and salts thereof, organic acids , Protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. The food composition of the present invention may also contain pulp for the production of fruit and vegetable drinks. These components may be used singly or in combination, and the proportion of such additives is generally selected in the range of 0.001 to 50 parts by weight based on the total weight of the composition.
이하, 본 발명을 실시예, 실험예 및 제조예에 의하여 상세히 설명한다.Hereinafter, the present invention will be described in detail by Examples, Experimental Examples and Preparation Examples.
단, 하기 실시예, 실험예 및 제조예는 본 발명을 구체적으로 예시하는 것이며, 본 발명의 내용이 실시예, 실험예 및 제조예에 의해 한정되는 것은 아니다.
However, the following Examples, Experimental Examples, and Production Examples specifically illustrate the present invention, and the contents of the present invention are not limited to Examples, Experimental Examples, and Production Examples.
<실시예 1> 연잎 추출물의 제조Example 1 Preparation of Lotus Leaf Extract
<1-1> <1-1> 열수Heat number 추출물 extract
연잎 가루(강화군 선원사에서 구입) 100g을 2.5 g/100 ㎖의 비율로 90℃ 증류수 4 ℓ에 2시간 동안 추출한 후, 추출물을 감압여과 시켜, 회전식 증발기(rotary vacuum evaporator)를 이용하여 수분을 제거한 후, 동결 건조 과정을 거쳐 18.8%의 수율로 총 18.8g을 수득하였다. 하기 <실험예>에 사용할 때에는 건조한 시료를 400 ㎎/㎖로 증류수에 섞어 경구투여한다.After extracting 100 g of lotus leaf powder (obtained from Ganghwa-gun) in 2 g of distilled water at 90 ° C. at a rate of 2.5 g / 100 ml for 2 hours, the extract was filtered under reduced pressure, and the water was removed using a rotary vacuum evaporator. After a freeze-drying process, a total of 18.8 g was obtained in a yield of 18.8%. When used in the following <Experimental Example>, a dry sample was mixed orally administered with distilled water at 400 mg / ml.
<1-2> 에탄올 추출물<1-2> ethanol extract
연잎 가루 100 g을 2.5 g/100 ㎖의 비율로 100% 에탄올 4ℓ에 2시간 동안 추출한 후, 추출물을 상기와 같은 방법으로 23%의 수율로 총 23 g을 수득하였다.
100 g of lotus leaf powder was extracted in 4 l of 100% ethanol at a rate of 2.5 g / 100 ml for 2 hours, and then the extract was extracted. A total of 23 g was obtained in the same manner as above in 23% yield.
<실시예 2> 정상식이와 고지방 식이의 제조Example 2 Preparation of Normal and High Fat Diets
고지방 식이는 정상식이에 비해서 라드(Lard)의 함량이 15배 높으며, 전분은 약 33% 감소되었으며, 당(Sucrose)은 약 20% 감소된 함량을 가지고 있다. High-fat diets have a 15-fold higher content of Lard, starch, about 33% less sugar, and sucrose, about 20% less than normal diets.
(retinyl palmitate pre-mix (250,000IU/g))Retinyl Palmitite Premix
(retinyl palmitate pre-mix (250,000 IU / g))
<< 실험예Experimental Example 1> 연잎 추출물 및 타우린의 체중감소 효과 1> Weight Loss Effect of Lotus Leaf Extract and Taurine
Sprague Dawley rat(현대바이오 구입, 5주령)을 정상식이군(8 마리), 고지방식이군(8 마리), 고지방식이에 연잎 추출물 투여군(8 마리), 고지방식이에 타우린 투여군(8 마리), 고지방식이와 연잎 추출물 및 타우린(8 마리)의 다섯 군으로 분류하여, 연잎 추출물을 400㎎/㎏ 체중/㎖을 6주간 매일 오전에 경구 투여하였다. 타우린의 경우 음용수에 3% 비율로 혼합하여 공급하였으며, 공급된 연잎 추출물과 타우린은 약 1:12의 비율로 추정된다. 정상식이와 고지방식이의 구성은 [표 1, 2 및 3]에 명시되었다. 실험 동물의 체중은 1주일에 1회씩 측정하였다. Sprague Dawley rats (purchased by Hyundai Bio, 5 weeks old) were fed a normal diet (8), a high fat diet (8), a high-fat diet containing lotus leaf extract (8), and a high fat diet. The group was divided into five groups, the high-fat diet and lotus leaf extract and taurine (8 rats), and the lotus leaf extract was orally administered at 400 mg / kg body weight / ml for 6 weeks every morning. In the case of taurine, 3% of the mixture was supplied to drinking water, and the lotus leaf extract and taurine were estimated to be about 1:12. The composition of the normal and high-fat diets is specified in Tables 1, 2 and 3. Body weights of the test animals were measured once a week.
그 결과, 시간이 경과함에 따라 고지방식이에서 체중의 증가가 나타남으로써 실험이 정상적으로 실행되는 것을 알 수 있었다. 고지방식이군은 정상식이군에 비해 유의적으로 체중이 증가하였으며, 고지방식이군과 연잎 추출물 및 타우린을 섭취하였을 때에는 연잎 혼합물 또는 타우린만을 섭취한 군에 비해서 더욱 체중이 감소된 결과를 확인할 수 있었다(도 1). 또한, 하기 표 4에 나타난 바와 같이, 고지방식이군을 공급한 군에 연잎 추출물과 타우린을 혼합하여 공급한 군에서의 체중 감소효과가, 연잎 추출물과 타우린을 각각 공급하였을 때보다 뛰어난 효과를 보임을 확인할 수 있다(표 4).
As a result, it was found that the experiment was performed normally as the weight gain appeared in the high-fat diet as time passed. The high-fat diet group gained significantly more weight than the normal diet group, and when the high-fat diet group, lotus leaf extract and taurine were ingested, the weight loss was higher than that of the group that consumed only the lotus leaf mixture or taurine (FIG. One). In addition, as shown in Table 4, the weight loss effect in the group supplied by mixing the lotus leaf extract and taurine in the group fed the high-fat diet group, showed an excellent effect than when the lotus leaf extract and taurine were respectively supplied It can be confirmed (Table 4).
<실험예 2> 연잎 추출물 및 타우린의 지방축적 억제 효과Experimental Example 2 Inhibitory Effect of Lotus Leaf Extract and Taurine on Fat Accumulation
<2-1> 지방 세포의 지방함량 관찰<2-1> Observation of fat content of fat cells
연잎 추출물 및 타우린의 지방축적 저해 효과를 알아보기 위하여, 6주간의 실험이 끝나고, 쥐를 희생시 일부 적출한 지방조직을 파라핀(paraffin) 방법을 응용하여 광학현미경으로 관찰하였다. In order to investigate the fat accumulation inhibitory effect of lotus leaf extract and taurine, after 6 weeks of experiment, the fat tissue extracted at the time of sacrifice of rats was observed by optical microscope using paraffin method.
조직 관찰을 위해서 적출한 간과 지방조직은 4℃의 보우인 용액(Bouin's solution)으로 6시간 동안 고정하였다. 고정된 조직은 흐르는 물에서 고정 시간과 동일하게 세척하였다. 세척된 조직은 60% 알코올을 거쳐 70%, 80%, 90% 알코올에 각각 10~20분간 처리하였다. 그 후 100% 알코올에서 30분간 2회 처리하여 탈수하였다. 완전히 탈수된 조직은 자일렌(xylene)과 알코올의 혼합액에서 30분 처리한 후 자일렌으로 1시간 동안 2회 처리하였다. 그리고 포매(embedding)는 용융점이 57℃인 파라핀(paraffin)으로 하였고, 포매된 조직의 슬라이드 표본 제작을 위하여는 조직절편기(rotary microtome)를 이용하여 약 8 ㎛로 절편하였다. 각 박편은 메이어즈 알부민(Mayer's albumin)으로 슬라이드에 부착하였고 건조용 배란기 (40±3℃)에 넣어 24시간 건조하였다. 건조된 슬라이드는 파라핀의 제거를 위하여 자일렌과 알코올을 1:1의 비율로 혼합한 용액에서 각 10분간 처리하였고 100%, 90%, 80%, 70%, 60% 알코올에서 각각 5분씩 처리하여 20분간 세척하였다. 그 후 헤마톡실린(hematoxylin)에서 약 1분, 에오신(eosin)에서 약 10분간 이중 염색하여 상기 탈수 방법의 역순으로 탈수하고 캐나다발삼(Canada balsam)으로 봉입하여 ZEISS (axiolab)현미경으로 관찰 촬영하였다. Liver and adipose tissues were removed for tissue observation and fixed for 6 hours with Bowin's solution at 4 ° C. Fixed tissues were washed in running water equal to fixation time. The washed tissue was treated with 70% alcohol, 80% alcohol, 90% alcohol for 10-20 minutes, respectively. Then, dehydrated by treating twice with 30% in 100% alcohol. Completely dehydrated tissues were treated with xylene and alcohol for 30 minutes and then treated with xylene twice for 1 hour. And embedding (embedding) was a paraffin (paraffin) having a melting point of 57 ℃, for the preparation of slide samples of embedded tissue was cut to about 8 ㎛ using a tissue micrograph (rotary microtome). Each slice was attached to a slide with Mayer's albumin and placed in a drying ovulator (40 ± 3 ° C.) for 24 hours. The dried slides were treated for 10 minutes in a mixture of xylene and alcohol in a ratio of 1: 1 to remove paraffins, and 5 minutes each at 100%, 90%, 80%, 70%, and 60% alcohol. Wash for 20 minutes. After that, the dye was double-stained for about 1 minute in hematoxylin and about 10 minutes in eosin and dehydrated in the reverse order of the dehydration method. .
그 결과, 도 2에 나타난 바와 같이, 고지방식이의 지방 세포는 정상식이군에 비해 지방이 축적되었는데, 연잎 추출물 및 타우린을 섭취한 쥐의 지방 세포에서는 지방의 축적이 매우 적음을 확인할 수 있었다(도 2).
As a result, as shown in Figure 2, fat cells of the high-fat diet was accumulated fat compared to the normal diet group, it was confirmed that the accumulation of fat is very small in the fat cells of rats fed lotus leaf extract and taurine (Fig. 2).
<2-2> 간 세포의 지방함량 관찰<2-2> Observation of fat content of liver cells
연잎 추출물 및 타우린의 지방축적 저해 효과를 알아보기 위하여, 6주간의 실험이 끝나고, 쥐를 희생시 일부 적출한 간 조직을 상기 기재한 파라핀 방법을 응용하여 광학현미경으로 관찰하였다.In order to investigate the fat accumulation inhibitory effect of the lotus leaf extract and taurine, after 6 weeks of experiment, the liver tissue was partially removed at the time of sacrifice of the rat was observed by optical microscope using the paraffin method described above.
그 결과, 도 3에 나타난 바와 같이, 고지방식이의 간 세포는 정상식이군에 비해 지방이 축적되어 세포의 모양이 커져 있으며, 불규칙한 것이 관찰되었으나, 연잎 추출물과 타우린을 함께 섭취한 쥐의 간 세포에서는 정상식이와 비슷한 모양의 세포가 관찰되며, 또한 고지방식이에 비하여 세포의 크기가 작으며, 지방의 축적이 매우 적음을 확인할 수 있었다(도 3).
As a result, as shown in Figure 3, the liver of the high-fat diet cells accumulate fat compared to the normal diet group, the shape of the cells is larger, irregularity was observed, but in the liver cells of rats ingested lotus leaf extract and taurine together Cells of a similar shape to the normal diet were observed, and also the cell size was smaller than that of the high fat diet, and it was confirmed that the accumulation of fat was very small (FIG. 3).
<실험예 3> 연잎 추출물 및 타우린의 고지혈증 예방 효과Experimental Example 3 Prevention of Hyperlipidemia of Lotus Leaf Extract and Taurine
연잎 추출물 및 타우린의 혈중 지질 감소 효과를 알아보기 위해서, 6 주간의 고지방식이 공급 기간이 끝난 후, 실험기간 종료 12시간 전부터 절식시킨 후, 에테르(ether)로 마취시켜 심장으로부터 채혈하였다. 채혈한 혈액은 원심분리관에 담아 3000 rpm에서 20분간 원심분리 하여 혈청을 분리하였고, -70℃에서 분석시까지 냉동보관하였다. In order to determine the blood lipid reduction effect of the lotus leaf extract and taurine, 6 weeks of high-fat diet was fed after 12 hours before the end of the experimental period, and then anesthetized with ether (ether) and collected from the heart. Blood was collected in a centrifuge tube and centrifuged at 3000 rpm for 20 minutes to separate serum, and frozen at -70 ° C until analysis.
혈청의 중성지방, 총 콜레스테롤, HDL-콜레스테롤 농도는 자동분석기기(Kuadro, Italy)를 이용해 분석하였으며, LDL 콜레스테롤 농도는 하기의 [수학식 1]인 Friedewald 식에 의해 산출하였다.
Serum triglyceride, total cholesterol, HDL-cholesterol concentration was analyzed using an automatic analyzer (Kuadro, Italy), LDL cholesterol concentration was calculated by the Friedewald equation [Equation 1] below.
그 결과, 도 4 에 나타난 바와 같이 총 콜레스테롤 양은 고지방식이를 공급한 군에서 정상식이에 비해 유의하게 증가함을 확인할 수 있었으며, 연잎 추출물 및 타우린을 함께 공급한 군에서는 고지방식이군에 비하여 유의적으로 총 콜레스테롤 양이 줄어드는 것을 확인할 수 있었다(도 4). As a result, as shown in FIG. 4, the total cholesterol level was significantly increased in the group fed with the high fat diet, compared with the normal diet, and the group fed with the lotus leaf extract and taurine was significantly higher than the high fat diet group. As a result, it was confirmed that the total cholesterol amount was reduced (FIG. 4).
또한, 도 5에 나타난 바와 같이, 총 콜레스테롤 양을 기준으로 HDL 콜레스테롤 양을 비교한 결과, 정상식이에 비해서 고지방식이를 공급할 때 수치가 감소하는 것을 확인할 수 있으며, 연잎 추출물과 타우린을 함께 공급하였을 때 연잎 추출물만을 단독 공급할 때보다 현저히 증가하는 것을 확인할 수 있었다(도 5).In addition, as shown in Figure 5, as a result of comparing the amount of HDL cholesterol on the basis of the total cholesterol amount, it can be seen that the value decreases when feeding a high-fat diet compared to the normal diet, lotus leaf extract and taurine were supplied together When the lotus leaf extract only when it was confirmed that significantly increased than when fed (Fig. 5).
아울러, 도 6에 나타난 바와 같이, LDL 콜레스테롤(low-density lipoprotein cholesterol)의 경우 연잎 추출물과 타우린을 공급하였을 때, 콜레스테롤 수치가 연잎 추출물만을 공급한 군에 비해서 감소하는 경향을 확인할 수 있었다(도 6).
In addition, as shown in Figure 6, in the case of low-density lipoprotein cholesterol (LDL cholesterol) when lotus leaf extract and taurine was supplied, it was confirmed that the cholesterol level tends to decrease compared to the group fed only lotus leaf extract (Figure 6 ).
<실험예 4> 간 손상 회복 측정Experimental Example 4 Liver Damage Recovery
연잎 추출물 및 타우린의 간손상 회복 효과를 알아보기 위해서, 6 주간의 고지방식이 공급 기간이 끝난후, 실험기간 종료 12시간 전부터 절식시킨후, 에테르(ether)로 마취시켜 심장으로부터 채혈하였다. 채혈한 혈액은 원심분리관에 담아 3000 rpm에서 20분간 원심분리 하여 혈청을 분리하였고, -70℃에서 분석시까지 냉동보관하였다. 간 손상 수치를 알아보기 위하여, GOT(glutamic oxaloacetic transaminase)와 GPT(glutamic pyruvic transaminase)의 혈중수치를 자동분석기기(Kuadro, Italy)를 이용해 분석하였다. In order to examine the liver damage recovery effect of lotus leaf extract and taurine, 6 weeks of high-fat diet after the end of the feeding period, fasted 12 hours before the end of the experimental period, anesthetized with ether (ether) and collected from the heart. Blood was collected in a centrifuge tube and centrifuged at 3000 rpm for 20 minutes to separate serum, and frozen at -70 ° C until analysis. To determine liver damage, blood levels of GOT (glutamic oxaloacetic transaminase) and GPT (glutamic pyruvic transaminase) were analyzed using an automatic analyzer (Kuadro, Italy).
그 결과, 도 7에 나타난 바와 같이, GPT와 GOT 모두 고지방식이를 공급받은 경우에 수치가 증가됨을 확인할 수 있었으며, 이는 연잎 추출물과 타우린을 공급하였을 때, 연잎 추출물을 단독으로 공급할 때보다 현저히 감소되는 것을 확인할 수 있었다. 특이할 만한 점은 GOT의 경우 연잎 추출물 및 타우린의 혼합물을 공급한 경우 정상식이보다 낮은 GOT 의 수치를 보인 점이다(도 7).As a result, as shown in Figure 7, both the GPT and GOT was confirmed that the value increased when fed a high-fat diet, which is significantly reduced when the lotus leaf extract and taurine supply, rather than the lotus leaf extract alone It could be confirmed. Of particular note is that GOT showed a lower GOT level than the normal diet when fed a mixture of lotus leaf extract and taurine (FIG. 7).
하기에 본 발명의 조성물을 위한 제조예를 제시한다.
The preparation examples for the compositions of the present invention are given below.
<제조예 1> 약학적 제제의 제조Preparation Example 1 Preparation of Pharmaceutical Formulation
<1-1> 산제의 제조<1-1> Preparation of powder
연잎 추출물 및 타우린 2 gLotus leaf extract and taurine 2 g
유당 1 g1 g lactose
상기의 성분을 혼합하고 기밀포에 충진하여 산제를 제조하였다.
The above components were mixed and packed in airtight bags to prepare powders.
<1-2> 정제의 제조<1-2> Preparation of Tablet
연잎 추출물 및 타우린 100 ㎎Lotus Leaf Extract and
옥수수전분 100 ㎎
유 당 100 ㎎100 mg of milk
스테아린산 마그네슘 2 ㎎2 mg of magnesium stearate
상기의 성분을 혼합한 후, 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조하였다.
After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.
<1-3> 캡슐제의 제조≪ 1-3 > Preparation of capsules
연잎 추출물 및 타우린 100 ㎎Lotus Leaf Extract and
옥수수전분 100 ㎎
유 당 100 ㎎100 mg of milk
스테아린산 마그네슘 2 ㎎2 mg of magnesium stearate
상기의 성분을 혼합한 후, 통상의 캡슐제의 제조방법에 따라서 젤라틴 캡슐에 충전하여 캡슐제를 제조하였다.
After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
<1-4> 환의 제조≪ 1-4 >
연잎 추출물 및 타우린 1 gLotus leaf extract and taurine 1 g
유당 1.5 gLactose 1.5 g
글리세린 1 gGlycerin 1 g
자일리톨 0.5 g0.5 g of xylitol
상기의 성분을 혼합한 후, 통상의 방법에 따라 1 환 당 4 g이 되도록 제조하였다.
After mixing the above components, it was prepared to be 4 g per ring according to a conventional method.
<1-5> 과립의 제조<1-5> Preparation of granules
연잎 추출물 및 타우린 150 ㎎Lotus Leaf Extract and
대두 추출물 50 ㎎Soybean extract 50 mg
포도당 200 ㎎200 mg of glucose
전분 600 ㎎600 mg of starch
상기의 성분을 혼합한 후, 30% 에탄올 100 ㎎을 첨가하여 60℃에서 건조하여 과립을 형성한 후 포에 충진하였다.
After mixing the above components, 100 mg of 30% ethanol was added and dried at 60 ° C. to form granules, and then filled in fabric.
<제조예 2> 식품의 제조 Preparation Example 2 Preparation of Food
<2-1> 과자 및 분식의 제조<2-1> Preparation of sweets and snacks
본 발명의 연잎 추출물 및 타우린 0.5~5.0 중량부를 밀가루에 첨가하고, 이 혼합물을 이용하여 빵, 케이크, 쿠키, 크래커 및 면류를 제조하여 건강 증진용 식품을 제조하였다.
Lotus leaf extract and taurine 0.5 ~ 5.0 parts by weight of the present invention was added to the flour, using the mixture to prepare bread, cakes, cookies, crackers and noodles to prepare a health food.
<2-2> 유제품의 제조<2-2> Production of Dairy Products
본 발명의 연잎 추출물 및 타우린 5~10 중량부를 우유에 첨가하고, 상기 우유를 이용하여 버터 및 아이스크림과 같은 다양한 유제품을 제조하였다.
Lotus leaf extract of the present invention and 5 to 10 parts by weight of taurine was added to the milk, using the milk to prepare a variety of dairy products such as butter and ice cream.
<2-3> 선식의 제조<2-3> Preparation of Wire
현미, 보리, 찹쌀, 율무를 공지의 방법으로 알파화시켜 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Brown rice, barley, glutinous rice, and yulmu were dried by a known method and dried, and the mixture was granulated to a powder having a particle size of 60 mesh.
검정콩, 검정깨, 들깨도 공지의 방법으로 쪄서 건조시킨 것을 배전한 후 분쇄기로 입도 60 메쉬의 분말로 제조하였다.Black soybeans, black sesame seeds, and perilla seeds were steamed and dried by a conventional method, and then they were prepared into powder having a particle size of 60 mesh by a pulverizer.
본 발명의 연잎 추출물 및 타우린을 진공 농축기에서 감압 농축하고, 분무, 열풍건조기로 건조하여 얻은 건조물을 분쇄기로 입도 60 메쉬로 분쇄하여 건조분말을 얻었다.The lotus leaf extract and taurine of the present invention were concentrated under reduced pressure in a vacuum concentrator, and the dried product obtained by drying with a spray and a hot air dryer was pulverized with a particle size of 60 mesh to obtain a dry powder.
상기에서 제조한 곡물류, 종실류 및 본 발명의 연잎 추출물 및 타우린의 건조분말을 다음의 비율로 배합하여 제조하였다.The grains, seeds and the lotus leaf extract of the present invention and the dry powder of taurine were prepared by blending in the following ratio.
곡물류(현미 30 중량부, 율무 15 중량부, 보리 20 중량부),Cereals (30 parts by weight brown rice, 15 parts by weight brittle, 20 parts by weight of barley),
종실류(들깨 7 중량부, 검정콩 8 중량부, 검정깨 7 중량부),Seeds (7 parts by weight of perilla, 8 parts by weight of black beans, 7 parts by weight of black sesame seeds)
본 발명의 연잎 추출물 및 타우린의 건조분말(3 중량부),Dry powder of lotus leaf extract and taurine of the present invention (3 parts by weight),
영지(0.5 중량부), 및Ganoderma lucidum (0.5 parts by weight), and
지황(0.5 중량부)
(0.5 parts by weight)
<제조예 3> 음료의 제조Preparation Example 3 Preparation of Beverage
연잎 추출물 및 타우린 1000 ㎎Lotus Leaf Extract and Taurine 1000 mg
구연산 1000 ㎎ Citric acid 1000 mg
올리고당 100 g 100 g oligosaccharides
매실농축액 2 g Plum concentrate 2 g
타우린 1 g 1 g of taurine
정제수를 가하여 전체 900 ㎖ Add 900 ml of purified water
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 ℓ용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강식품 제조에 사용한다. After mixing the above components according to the conventional healthy beverage manufacturing method, and stirred and heated at 85 ℃ for about 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and then refrigerated and stored Used in the manufacture of the health food of the invention.
상기 조성비는 비교적 기호 음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.
Although the composition ratio is a composition suitable for a preferred beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and intended use.
상기에서 보는 바와 같이, 본 발명의 연잎 추출물 및 타우린은 체중감소, 지방 및 간 조직의 지방 축적을 억제하며, 혈중 HDL 콜레스테롤을 증가시키는 반면, LDL 콜레스테롤을 감소시키는 효과를 가지고 있으며, 고지방식이로 인해 높아진 간 손상 수치인 GPT 및 GOT수치를 낮추어 간 손상을 회복시키는 효과를 가지므로 대사성 질환인 고지혈증 또는 지방간의 예방 및 치료 효과를 갖는 조성물 및 건강식품으로 유용하게 사용될 수 있다.As seen above, the lotus leaf extract and taurine of the present invention inhibit weight loss, fat accumulation of fat and liver tissue, increase the HDL cholesterol in the blood, while having the effect of reducing LDL cholesterol, high-fat diet Due to the effect of restoring liver damage by lowering the GPT and GOT levels, which are elevated liver damage, it can be usefully used as a composition and health food having a prophylactic and therapeutic effect on metabolic diseases such as hyperlipidemia or fatty liver.
Claims (4)
A pharmaceutical composition for preventing and treating fatty liver, comprising water or ethanol extract of lotus leaf ( Nelumbo nucifera leaf) and taurine as active ingredients.
Health food for the prevention and improvement of fatty liver containing water or ethanol extract of lotus leaf and taurine as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100015502A KR101176435B1 (en) | 2010-02-22 | 2010-02-22 | Composition for the prevention and treatment metabolic disorders comprising extracts of Nelumbo nucifera leaf and Taurine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100015502A KR101176435B1 (en) | 2010-02-22 | 2010-02-22 | Composition for the prevention and treatment metabolic disorders comprising extracts of Nelumbo nucifera leaf and Taurine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20110096194A KR20110096194A (en) | 2011-08-30 |
| KR101176435B1 true KR101176435B1 (en) | 2012-08-30 |
Family
ID=44931464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020100015502A KR101176435B1 (en) | 2010-02-22 | 2010-02-22 | Composition for the prevention and treatment metabolic disorders comprising extracts of Nelumbo nucifera leaf and Taurine |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101176435B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190129245A (en) | 2018-05-10 | 2019-11-20 | 한국식품연구원 | Polysaccharide fraction isolated from Nelumbo nucifera leaf with immune-enhancing activity and method for producing the same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101886299B1 (en) * | 2017-10-31 | 2018-08-16 | 경희대학교 산학협력단 | Compositions for Preventing, Improving or Treating Obesity and Metabolic Diseases Comprising Combined Extracts of Peach Blossom and Lotus Leaf |
-
2010
- 2010-02-22 KR KR1020100015502A patent/KR101176435B1/en active IP Right Grant
Non-Patent Citations (2)
| Title |
|---|
| 생약학회지 36(3), pp. 229-234, 2005. 1부.* |
| 한국영양학회 1997년도 춘계학술대회 초록, pp.46-46, 1997. 1부.* |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190129245A (en) | 2018-05-10 | 2019-11-20 | 한국식품연구원 | Polysaccharide fraction isolated from Nelumbo nucifera leaf with immune-enhancing activity and method for producing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110096194A (en) | 2011-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5685752B2 (en) | Blood flow promoting agent | |
| EP2303297B1 (en) | Water-soluble extracts of artemisia dracunculus (tarragon) for improvement of glucose metabolism | |
| KR20160144791A (en) | Composition for relieving menopausal symptom | |
| JP2018080148A (en) | Composition for preventing and/or improving climacteric symptom | |
| KR101902932B1 (en) | A composition for preventing, improving or treating alcoholic gastritis of the extracts from the aerial parts except flower and root of Cirsium japonicum and Taraxacum coreanum | |
| JP2008266223A (en) | Formulation for ameliorating excessive sensitivity to cold | |
| KR101176435B1 (en) | Composition for the prevention and treatment metabolic disorders comprising extracts of Nelumbo nucifera leaf and Taurine | |
| JP2017515827A (en) | Composition for preventing and treating male infertility containing mixed herb extract as active ingredient and use thereof | |
| KR102075836B1 (en) | Composition for preventing or treating menopausal syndrome of women comprising Aristotelia chilensis extract, Angelica sinensis extract and Passiflora incarnata extract as an active ingredient | |
| KR101018403B1 (en) | composition comprising the extract of soybean leaves for the prevention?delay or treatment of gout | |
| WO2005094858A1 (en) | Antidiabetic composition | |
| KR20160114841A (en) | Composition for improvement or treatment of Fat comprising Eucommiae ulmoides Oliv. Bark. extract or Adiponectin isolated therefrom as active ingredient | |
| KR102410771B1 (en) | Composition for preventing or treating sarcopenia comprising blueberry extract | |
| KR20110006921A (en) | Composition for prevention and treatment of type 2 diabetes containing extract of gastrodia elata blume as an active ingredient | |
| KR101157508B1 (en) | Composition for prevention and treatment metabolic disorders comprising extracts of Nelumbo nucifera root | |
| KR100888068B1 (en) | Compositions for suppressing obesity | |
| KR20120089045A (en) | A composition comprising powder of amphicarpaea bracteata subsp.edgeworthii(benth.) h.ohashi and the extract thereof for preventing and treating diabetes mellitus and diabetic complication | |
| KR20050100890A (en) | Composition comprising the extract of acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
| KR101018404B1 (en) | Compositions for reducing cholesterol comprising extracts of Vaccinium oldhami Miquel leaf as an active ingredient | |
| JP5608877B2 (en) | Swelling preventive and oral composition | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| KR101438278B1 (en) | Composition for Prevention or Treatment of Circulatory Disorder Comprising AFG | |
| KR100686362B1 (en) | A composition comprising an extract of zizyphus jujuba mill. var. inermis rehder for treating and preventing obesity | |
| KR20120033443A (en) | Antifatigue composition comprising the extracts, fractions or isolated compounds of eisenia bicyclis and process for preparation thereof | |
| KR20050041272A (en) | Composition comprising the extract of complex hurb medicines for growth stimulation, or treatment and prevention of growth retardation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20150626 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20160602 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20170807 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20190829 Year of fee payment: 8 |